Type to search

Stéphane Bancel

Share
Stéphane Bancel
Founding CEO

Stéphane Bancel

Posts Featuring Stéphane Bancel

James Mock Joins Moderna as Chief Financial Officer | Pharmtech Focus

James Mock Joins Moderna as Chief Financial Officer

Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-containing Bivalent Booster in the UK | Pharmtech Focus

Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna’s Omicron-containing Bivalent Booster in the UK

Moderna and the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-containing Bivalent Candidates; EC Purchases Additional 15 Million Doses | Pharmtech Focus

Moderna and the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-containing Bivalent Candidates; EC Purchases Additional 15 Million Doses

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union | Pharmtech Focus

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union

Moderna's Omicron-containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared to Currently Authorized Booster | Pharmtech Focus

Moderna’s Omicron-containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared to Currently Authorized Booster

Moderna Announces First Participant Dosed in a Phase 1 Trial of Its Nipah Virus mRNA Vaccine, mRNA-1215 | Pharmtech Focus

Moderna Announces First Participant Dosed in a Phase 1 Trial of Its Nipah Virus mRNA Vaccine, mRNA-1215

Moderna Announces Bivalent Booster mRNA -1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants Ba.4 and Ba.5 | Pharmtech Focus

Moderna Announces Bivalent Booster mRNA -1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants Ba.4 and Ba.5

Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom | Pharmtech Focus

Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom

Moderna Announces Omicron-containing Bivalent Booster Candidate Mrna-1273.214 Demonstrates Superior Antibody Response Against Omicron | Pharmtech Focus

Moderna Announces Omicron-containing Bivalent Booster Candidate Mrna-1273.214 Demonstrates Superior Antibody Response Against Omicron

Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day | Pharmtech Focus

Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day

Arpa Garay Joins Moderna as Chief Commercial Officer | Pharmtech Focus

Arpa Garay Joins Moderna as Chief Commercial Officer

Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023 | Pharmtech Focus

Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023

Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant | Pharmtech Focus

Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

Moderna Announces EU and EEA Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to Help End COVID-19 Pandemic in Low Income Countries | Pharmtech Focus

Moderna Announces EU and EEA Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to Help End COVID-19 Pandemic in Low Income Countries

Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022 | Pharmtech Focus

Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022

Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year | Pharmtech Focus

Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year

Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older | Pharmtech Focus

Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older

Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada | Pharmtech Focus

Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

Dr. Paul Burton to Join Moderna as Chief Medical Officer | Pharmtech Focus

Dr. Paul Burton to Join Moderna as Chief Medical Officer

Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union | Pharmtech Focus

Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union

UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility | Pharmtech Focus

UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility

Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June | Pharmtech Focus

Moderna Announces TeenCOVE Study of COVID-19 Vaccine (mRNA-1273) in Adolescents Meets Primary Endpoint

Moderna Announces New Supply Agreement with Australia for 25 Million Doses of its COVID-19 Vaccine | Pharmtech Focus

Moderna Announces New Supply Agreement with Australia for 25 Million Doses of its COVID-19 Vaccine

Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses | Pharmtech Focus

Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses

Moderna Announces Expansion of its Manufacturing Technology Center in Massachusetts | Pharmtech Focus

Moderna Expands Manufacturing Technology Center

Moderna New Supply Agreement with Israel for 2022 | Pharmtech Focus

Moderna New Supply Agreement with Israel for 2022

Moderna announces FDA Authorization of Moderna COVID-19 vaccine in U.S. | Pharmtech Focus

Moderna announces FDA Authorization of Moderna COVID-19 vaccine in U.S.